Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial

Objective Vunakizumab, a novel IL-17A inhibitor, has demonstrated satisfactory efficacy and safety for the treatment of moderate-to-severe plaque psoriasis. This analysis aimed to assess the impact of treatment interruption on the efficacy and safety of vunakizumab in the treatment of this disease. Methods This post-hoc analysis used data from a phase 3 trial of vunakizumab (NCT04839016) that enrolled patients with moderate-to-severe plaque psoriasis. A total of 460 patients received vunakizumab treatment and were included in this analysis. Results Over the 52-week treatment, 223 patients had one or more treatment interruption, and 237 patients had no treatment interruption. At week 52, patients with treatment interruption had lower achievement rates for Psoriasis Area and Severity Index (PASI) 75 (77.1% vs. 97.9%), PASI 90 (67.3% vs. 94.1%), PASI 100 (49.8% vs. 75.9%), and static Physician’s Global Assessment of 0/1 (62.8% vs. 93.7%) than those without interruption (all P